Sunshine Biopharma (NASDAQ:SBFM) Downgraded by Wall Street Zen to Sell

Sunshine Biopharma (NASDAQ:SBFM) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Sunshine Biopharma Price Performance

Shares of SBFM stock opened at $1.56 on Friday. Sunshine Biopharma has a 12-month low of $1.17 and a 12-month high of $6.99. The firm has a market capitalization of $7.11 million, a price-to-earnings ratio of -0.01 and a beta of 1.44. The business has a 50 day simple moving average of $1.49 and a 200 day simple moving average of $1.94.

Sunshine Biopharma (NASDAQ:SBFM) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.44) earnings per share (EPS) for the quarter. The firm had revenue of $8.90 million for the quarter. Sunshine Biopharma had a negative net margin of 13.88% and a negative return on equity of 21.25%.

Hedge Funds Weigh In On Sunshine Biopharma

A hedge fund recently bought a new stake in Sunshine Biopharma stock. Connective Capital Management LLC purchased a new stake in shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 11,345 shares of the company’s stock, valued at approximately $34,000. Connective Capital Management LLC owned approximately 0.93% of Sunshine Biopharma as of its most recent filing with the SEC. 41.98% of the stock is owned by institutional investors.

About Sunshine Biopharma

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.